TWTara White

Tara White

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tara White has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Barbara De Moerloose

    Department of Pediatric Hematology‐Oncology and Stem Cell Transplantation Ghent University Hospital Ghent Belgium

    1 shared publication
  • Bianca Frederika Goemans

    Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands

    1 shared publication
  • C. Michel Zwaan

    Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands

    1 shared publication
  • Daniela Cianci

    Julius Center for Health Sciences and Primary Care University Medical Center Utrecht Utrecht University Utrecht the Netherlands

    1 shared publication
  • Gertjan Kaspers

    Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands

    1 shared publication
  • Henrik Hasle

    Department of Pediatrics Aarhus University Hospital Aarhus Denmark

    1 shared publication

Latest Publications

  • Open Access

    Clinical outcomes of second relapsed and refractory first relapsed paediatric AML: A retrospective study within the NOPHO‐DB SHIP consortium

    by Tara White, Gertjan Kaspers, Jonas Abrahamsson, Nira Arad‐Cohen, Daniela Cianci, Jose Fernandez, Shau‐Yin Ha, Henrik Hasle, Barbara De Moerloose, C. Michel Zwaan, et al.

    Summary: As treatments for second relapsed and refractory first relapsed paediatric AML transition from purely palliative to more commonly curative in nature, comparative data is necessary for evaluating the effectiveness of emerging treatment options. Furthermore, little is known about predictors of prognosis following third‐line therapy. From 2004 until 2019, 277 of the 869 patients enrolled in NOPHO‐DB SHIP consortium trials experienced a first relapse and, of these patients, 98 experienced refractory first relapse and 59 a second relapse. Data on patient and disease characteristics within this cohort of 157 patients was analysed to determine probability of overall survival (pOS) and to identify factors influencing survival. Data on early treatment response and complete remission were not available. One and 5‐year pOS were 22 ± 3% and 14 ± 3%, respectively. There was no statistically significant difference in survival between refractory first relapsed and second relapsed AML. Factors influencing prognosis included: late relapse, type of third‐line treatment, FLT3 mutational status, and original treatment protocol. These data provide a baseline for evaluating the effectiveness of emerging therapies for the treatment of children with refractory first relapsed and second relapsed paediatric AML and evidence that select patients receiving third‐line therapy can be cured.